HOME >> MEDICINE >> NEWS
Light-weight heparin has heavy-weight results in heart attack treatment

DALLAS, Heart attack patients treated with the blood-thinner enoxaparin a low molecular weight heparin plus a clot dissolver were significantly less likely to die or have repeat heart attacks within 30 days compared to patients who received unfractionated heparin (UFH), according to a Rapid Track article in todays Circulation: Journal of the American Heart Association.

Patients in the study had what are known as ST-segment elevation myocardial infarctions, which are the most severe type of heart attack. We have very encouraging data but the evidence is not yet sufficient to say that enoxaparin should be standard treatment for severe heart attacks, says Elliott Antman, M.D., associate professor of medicine at Harvard Medical School and director of the coronary care unit of Brigham and Womens Hospital in Boston. However, the data suggest we should pursue a larger clinical trial.

Enoxaparin previously has been shown to be superior to unfractionated heparin (another blood thinner) for patients with milder heart attacks (non-ST segment elevation). It can be given as a simple injection, rather than the continuous infusion required with UFH, and it does not require frequent testing of the patients blood clotting status.

The researchers report their findings from the ENTIRE-TIMI 23 study. This international study involved 483 patients who presented with severe heart attacks at hospitals in the United States and Europe. Participants were randomly assigned either standard reperfusion with a full dose of the clot-dissolving drug tenecteplase (TNK) or combination therapy with abciximab and a half dose of TNK and either unfractionated heparin (UFH) or enoxaparin. Abciximab is a drug that helps keep blood platelets from sticking together to form clots.

The study was designed to evaluate enoxaparin as adjunctive treatment with various forms of reperfusion therapies (TNK, abciximab). To evaluate reperfusion (blood flow) researchers used the TIMI
'"/>

Contact: Carole Bullock
carole.bullock@heart.org
214-706-1279
American Heart Association
4-Mar-2002


Page: 1 2

Related medicine news :

1. The protective effects of heparin in preventing miscarriages in lupus patients
2. Newer formulation of heparin improves outcomes for suspected heart attack patients
3. New studies show mixed results on epilepsy drugs and birth defects
4. Study of obese diabetics explains why low-carb diets produce fast results
5. Sharing clinical trial results with participants may be beneficial
6. Emergency clopidogrel could save thousands of lives46,000-patient heart attack trial results
7. Similar results found in both older and younger patients undergoing weight-loss surgery
8. OHSU researcher says FDA could broaden access to results of clinical drug trials
9. Kinder, gentler procedure gives superior results for stem cell transplants
10. Good results with only one egg in in-vitro fertilization
11. Holiday feasting could sabotage liposuction results

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/24/2017)... ... July 24, 2017 , ... Axiad IDS , ... announced it has partnered with WALLIX to expand its solution to help ... , There are a number of ways to address the authentication requirements within ...
(Date:7/24/2017)... ... July 24, 2017 , ... A CDC study shows that, although people are taking more ... 18 to 29), had at least one case of sunburn within the past year. It’s ... people to ignore the issue. However, only recently have people become conscientious of the risks ...
(Date:7/24/2017)... ... July 24, 2017 , ... The ... Harbor, MD. This year's theme focuses on the new ISO/IEC 17025 standards. This ... and integrity in testing and calibration will be changed. , As an ...
(Date:7/24/2017)... ... 24, 2017 , ... Paul Vitenas, MD, FACS is excited to report that ... to attend Allergan’s recent meeting with their Plastics Advisory Board. As one of the ... is bringing a newly defined structure to the aesthetics market. Dr. Vitenas , ...
(Date:7/24/2017)... ... July 24, 2017 , ... Committed ... they have enrolled over 100,000 children in their treatment program. Clubfoot is a ... in areas where treatment is limited or non-existent. Without intervention, these children are ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... Did you know that PhRMA member companies invested $65.5 ... spending on brand medicines, generics and the supply chain account for ... just half of this (7 percent)? Or that the ... venture capital investments in high-growth biopharmaceutical startups? ... The biopharmaceutical ...
(Date:7/14/2017)... DUBLIN , July 14, 2017 Endo International plc ... results on Tuesday, August 8, 2017.  Members of its senior management ... financial markets open at 8:30 a.m. ET. The ... (866) 497-0462, International (678) 509-7598, and the passcode is 45397076. ... A replay of the ...
(Date:7/12/2017)... -- CarpalAID is a revolutionary new product that relieves painful carpal ... tunnel syndrome affects more than 8 million people a year. Women ... The common methods of treating CTS are painful surgery, the use ... gloves. ... CarpalAID is a clear patch worn on the palm of the ...
Breaking Medicine Technology:
Cached News: